Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by American International Group Inc.

American International Group Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 125,780 shares of the medical equipment provider’s stock after selling 4,023 shares during the period. American International Group Inc. owned 0.18% of Lantheus worth $7,798,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in LNTH. FMR LLC increased its position in Lantheus by 198.2% in the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after buying an additional 1,426,465 shares during the period. Norges Bank acquired a new stake in Lantheus in the fourth quarter worth $29,956,000. Reinhart Partners LLC. increased its position in Lantheus by 50.4% in the fourth quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock worth $84,089,000 after buying an additional 454,753 shares during the period. American Century Companies Inc. increased its position in Lantheus by 41.9% in the third quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after buying an additional 384,093 shares during the period. Finally, Avidity Partners Management LP grew its stake in shares of Lantheus by 127.8% in the third quarter. Avidity Partners Management LP now owns 558,400 shares of the medical equipment provider’s stock worth $38,798,000 after purchasing an additional 313,300 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent analyst reports. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Mizuho increased their price target on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. B. Riley increased their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Truist Financial increased their price target on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Finally, JMP Securities reissued a “market outperform” rating and issued a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $99.17.

Lantheus Trading Down 1.8 %

Shares of LNTH stock opened at $81.13 on Thursday. The stock has a 50-day simple moving average of $74.81 and a 200 day simple moving average of $65.65. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $94.47. The stock has a market capitalization of $5.62 billion, a P/E ratio of 12.39 and a beta of 0.56. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The business had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at approximately $4,990,171.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total value of $1,454,957.87. Following the completion of the transaction, the director now owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The disclosure for this sale can be found here. Insiders sold 32,269 shares of company stock worth $2,557,300 in the last quarter. 2.10% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.